Bullish option flow detected in Apellis Pharmaceuticals with 2,130 calls trading, 1.4x expected, and implied vol increasing over 2 points to 86.51%. Nov-23 50 calls and Nov-23 70 calls are the most active options, with total volume in those strikes near 1,200 contracts. The Put/Call Ratio is 0.12. Earnings are expected on November 1st.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results
- Apellis says journal published 24-month result from Phase 3 OAKS, DERBY studies
- The Lancet Publishes 24-Month Results from Phase 3 Studies of SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy (GA)
- Apellis Pharmaceuticals put volume heavy and directionally bearish
- Apellis to present positive Phase 2 NOBLE results of pegcetacoplan
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue